HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYN
CGTLive’s Weekly Rewind – February 3, 2023

Review top news and interview highlights from the week ending February 3, 2023.

FDA Blocks 4D’s Gene Therapy Program for Fabry, Clears IND for Diabetic Macular Edema

The clinical hold comes a few weeks after the company announced it was stopping enrollment in the phase 1/2 clinical trial.

Raj Mehra, PhD, and Krishna Subramanian, PhD, on Striving For Disease-Modifying Therapies in Parkinson Disease

Mehra and Subramanian discussed preclinical research with the investigational gene therapy SLS-004.

Considerations for Use of TILs versus CAR T-cell Therapies

Shared insight on the benefits and drawbacks of using tumor-infiltrating lymphocyte therapy for treatment of solid tumors, as compared to chimeric antigen receptor (CAR) T-cell therapy.

An Overview on Tumor-Infiltrating Lymphocyte Therapy for Solid Tumors

Expert perspectives on the mechanism of action behind tumor-infiltrating lymphocyte (TIL) therapy and how it might address existing unmet needs in the treatment of solid tumors, including melanoma and non-small cell lung cancer.

Gene Therapy Trial Doses First Patient With Wet AMD in China

The phase 1 clinical trial is the second of Frontera’s trials to begin dosing in 2023.